Horizon Reports First Patient Enrollment in P-IIb Trial of HZN-825 for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Shots: The company has enrolled the 1st patient in a P-IIb trial to evaluate HZN-825 (300mg, qd/bid) in a ratio (1:1:1) in 300 patients with […]